Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP4 | P49662 | 1/20 | 0.30 |
| ▸ | CASP5 | P51878 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20912789 | 0.83 | PDCD1 (0.43) | HTR2CHTR2AHRH4NCF1PDCD1 | |
| Hydrochloric Acid SCHEMBL23778209 | 0.81 | PDCD1 (0.43) | HTR2CHTR2AHRH4NCF1PDCD1 | |
| Hydrochloric Acid SCHEMBL23779043 | 0.81 | PDCD1 (0.43) | HTR2CHTR2AHRH4NCF1PDCD1 | |
| SCHEMBL27329671 | 0.78 | PDCD1 (0.37) | HTR2CHTR2ANCF1PDCD1CD274 | |
| SCHEMBL20517214 | 0.78 | HTR2C (0.37) | HTR2CHTR2APDCD1CD274CASP1 | |
| SCHEMBL26495272 | 0.75 | HTR2C (0.35) | HTR2CHTR2APDCD1CD274 | |
| SCHEMBL25594644 | 0.74 | GRM5 (0.40) | HTR2CHTR2AHRH4PDCD1CD274 | |
| SCHEMBL27329663 | 0.74 | HTR2C (0.34) | HTR2CHTR2APDCD1CD274 | |
| SCHEMBL20092261 | 0.73 | — | — | |
| SCHEMBL20461181 | 0.73 | PDCD1 (0.36) | HTR2CHTR2AHRH4PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | HTR2C 4513/4885HTR2A 3672/4885HRH4 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.